托瑞米芬治疗乳腺囊性增生症临床疗效的初步观察

为了观察托瑞米芬(枢瑞)治疗乳腺囊性增生症的临床疗效。选取临床症状及体征均明显的乳腺囊性增生 症100例,试验组(50例)给予托瑞米芬40mg口服,1次/d,连用3个月,并根据乳腺活检后ER结果分成ER(+)及 ER(-)两个亚组观察其临床疗效。对照组(50例)给予中成药(乳癖散结胶囊)对症治疗,连用3个月。托瑞米芬治 疗乳腺囊性增生症的临床有效率为80%(40/50),对ER(+)患者疗效更高,有效率92.9%(26/28)。无明显的毒副 反应。乳癖散结胶囊对照组临床有效率为58%(29/50),两组比较差异有统计学意义,0.01

Clinical observation on breast cystic hyperplasia treated with toremifene

To observe the clinical effects of the treatment with toremifene on breast cystic hyperplasia. A total fo 100 patients who suffered from Breast Cystic Hyperplasia with obvious symptoms and signs were randomized into Toremifene treatment group (50 cases) with toremifene 40 mg daily for three months and control group (50 cases) with Chinese medicine (RUPI SANJIE) daily for three months. They were further divided into two subgroups: ER positive group and ER negative group according to the results of estrogen receptor (ER) in the tissues of mamma glands. The clinical effects were observed subsequently. The clinical effective rate of Toremifene on breast cystic hyperplasia was 80%(40/50), and it was up to 92.9% (26/28) in patients with ER positive. No obvious adverse effects were observed in the group. However, the clinical effective rate of R-UPI SANJIE was 58% (29/50). There was a significant difference between the two groups, 0.01